EP
PLRX icon

Eversept Partners’s Pliant Therapeutics PLRX Stock Holding History

Eversept Partners’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.12M Buy
891,425
+49,402
+6% +$62.4K 0.06% 104
2025
Q4 		$1.03M Buy
842,023
+17,429
+2% +$26.2K 0.05% 98
2025
Q3 		$1.22M Buy
+824,594
New +$1.26M 0.08% 75
2023
Q1 		– Sell
-137,423
Closed -$2.66M – 75
2022
Q4 		$2.66M Sell
137,423
-156,680
-53% -$3.28M 0.23% 45
2022
Q3 		$6.14M Buy
+294,103
New +$5.63M 0.53% 36

Other funds holding PLRX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Eversept Partners's PLRX Position: Q1 2026 in Review

Eversept Partners increased its Pliant Therapeutics (PLRX) stake by 5.9% in Q1 2026, buying an estimated $62.4K and bringing the position to 891,425 shares worth $1.12M. The position accounts for 0.06% of the portfolio, ranked #104.

Eversept Partners first reported a position in PLRX in Q3 2022 and has held it in 5 quarters since. The position peaked at $6.14M in Q3 2022. 91 funds tracked by Wall St. Rank hold PLRX as of Q1 2026.

  • Eversept Partners held 891,425 shares of Pliant Therapeutics worth $1.12M as of Q1 2026.
  • Eversept Partners bought 49,402 Pliant Therapeutics shares in Q1 2026, an estimated $62.4K.
  • Pliant Therapeutics made up 0.06% of Eversept Partners's portfolio in Q1 2026, its #104 holding.
  • Eversept Partners first reported a position in Pliant Therapeutics in Q3 2022 and has held it in 5 quarters since.
  • Eversept Partners's Pliant Therapeutics position peaked at $6.14M in Q3 2022.
  • 91 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q1 2026.

Based on Eversept Partners's 13F filing for Q1 2026, filed 15 May 2026.